1st UK Interdisciplinary Breast Cancer Symposium

Slides:



Advertisements
Similar presentations
TOP2A IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN UNSELECTED BREAST CANCER Amit Pancholi Molecular Profiling of Breast Cancer: Predictive Markers of Long.
Advertisements

Which of the following increases a women’s risk for Breast Cancer? A.Starting her menses at age 14 or older B.Breastfeeding C.Extremely dense breast tissue.
A trial for women with –‘Triple negative’ breast cancer (TNBC) –Localised to breast +/- lymph nodes –Recommended standard treatment involves NEPTUNE Taxane.
Breast Cancer Risk and Risk Assessment Models
Breast Cancer Screening, Family History Assessment and New Innovations Miss Karina Cox Consultant Breast and Oncoplastic Surgeon.
Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery
Cancer Genetics. Issues Colorectal guidelines – Awaiting publication of coloproctologists guidance – SIGN / QIS update started Breast / ovarian – Breast.
By Rachel, Xiao Xia, Helen. Introduction Definition Symptoms Causes Prevention Treatment Prognosis Statistics Conclusion.
Breast Screening. NHS Breast Screening Programme Introduced in 1988 Invites women from age group for screening every 3 yrs. Age extension roll-out.
Ductal Carcinoma in situ
The Cancer Pedigree BRCA What?. Outline Introduction: Understanding the weight of genetics in Ovarian Breast Cancer BRCA 1 and BRCA 2 Genes – Function.
Elshami M.Elamin, MD Medical Oncologist Central Care Cancer Center Wichita, KS, USA
Breast Cancer Clinical Cases Daniel A. Nikcevich, MD, PhD SMDC Cancer Center April 20, 2009.
BREAST CANCER GROUP 6 :  Nuraini Ikqtiarzune Haryono( )  Tri Wahyu Ningsih ( )  Rani Yuswandaru ( )  Anita Rheza Fitriana Putri( )
Jo Anne Zujewski, MD Center for Global Health National Cancer Institute, U.S.A. Dar es Salaam September 11, 2014 Breast Cancer Risk Factors and Prevention.
Ductal Carcinoma In Situ (DCIS)
 Determining the Nature of a Breast Abnormality  It is a procedure that may be used to determine whether a lump is a cyst (sac containing fluid) or a.
Breast Carcinoma. Anatomy Epidemiology: 10% 17.1/10 28/10 46/ m world wide 6% develop cancer of the breast in their lifetime. 50,000 to 70,000.
Dubsky P et al. Proc SABCS 2012;Abstract S4-3.
Katie Ludwig FY1.   50, 285 New cases of breast cancer  11, 716 deaths  78% - 10 year survival rates  27% preventable cases  Source:
Breast Cancer By: Christen Scott.
Shiva Sharma SHO to Professor Redmond.  Introduction  Increased risk groups  Consideration of genetic testing  Management of patients with mutation.
Snyder D, Heidel RE, Panella T, Bell J, Orucevic A University of Tennessee Medical Center – Knoxville Departments of Pathology, Surgery, and Medicine BREAST.
Breast Cancer Prevention Art or Science? Kristi McIntyre M.D. Texas Oncology 2005.
Breast Cancer. Breast cancer is a disease in which malignant cells form in the tissues of the breast – “National Breast Cancer Foundation” The American.
Chemoprevention of cancer Dr Manal Kahwaji Cancer fighting day Feb 2, 2016.
Annals of Oncology 24: 2206–2223, 2013 R3 조영학
Treatment Options for Postmenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer Recent Trials and Future Directions Harold Burstein,
The Elliott Breast Center * Baton Rouge, LA *
Overview: Breast Cancer- Surgical Treatment
Nicolas Ajkay, MD, FACS Assistant Professor of Surgery
Challenges for the treatment of breast cancer
San Antonio Breast Cancer Symposium, December 6-10, 2016
Breast Cancer Updates Risks, Genetics, DCIS
Case 3 Jane McNicholas Consultant Oncoplastic Breast Surgeon
Volume 12, Issue 9, Pages (September 2011)
Indications for Breast MR Imaging
Breast Cancer Protocol
Operative Approach and
Dr Amit Gupta Associate Professor Dept Of Surgery
Breast conserving surgery (BCT): Every millimetre counts
Surgical Management of the Breast in Breast Cancer
Breast Cancer Anne Kelly RN,MS,NP-C AOCNP October 25,2017
Breast cancer: patterns and risk factors in older and younger women (June 2014) Breast cancer incidence is low in women under the age of 50 and has remained.
นายแพทย์ธราธร ตุงคะสมิต นายแพทย์ชำนาญการพิเศษ โรงพยาบาลมะเร็งอุดรธานี
THBT neoadjuvant endocrine therapy is to be used in post-menopausal breast cancer woman Antonino Grassadonia Università «G. D’Annunzio» – Chieti-Pescara.
Case scenario- Breast Lump
Marcelo Calil Instituto Brasileiro de Controle do Câncer
But how to treat those with positive SLNB? Results and Discussion
Breast Screening and Risk Assessment
Thanh Nhan Hospital MALE BREAST CANCER: CASE REPORT
Dr. Sura Obay Al-Dewachi
Breast Health Katherine B. Lee, MD, FACP April 26, 2018.
Peter T. Simpson, Leonard M. Da Silva, Sunil R. Lakhani  Cancer Cell 
Breast Imaging Ravi Adhikary, MD.
Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results.
徐慧萍1 羅竹君1,2 郭耀隆1 李國鼎1 國立成功大學醫學院附設醫院外科部1 國立成功大學醫學院臨床醫學研究所2
Melanoma and Breast cancer
Mastectomy and Reconstruction In Asian Breast Cancer Patients
Managing gBRCA-Positive Metastatic Breast Cancer
Figure 1 Differences in bladder cancer between genders
Effect of Obesity on Prognosis after Early Breast Cancer
Breast Cancer.
HBOC Genetic counseling: major concerns and communication skills
Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.
THE LANCET Oncology Volume 19, No. 1, p27–39, January 2018
Marion C.W. Henry, MD Yale University
Diagnosis of breast cancer in women age 40 and younger: Delays in diagnosis result from underuse of genetic testing and breast imaging 95% of patients.
Fig. 2. Axial contrast-enhanced T1-weighted subtraction MRI obtained 150 s after contrast injection in a 57-year-old post-menopausal woman treated for.
Principles and Practice of Radiation Therapy
Presentation transcript:

1st UK Interdisciplinary Breast Cancer Symposium Manchester January 2018 Some Musings

POETIC Trial Multicentre, phase III, randomised trial for post menopausal women with ER/PR positive invasive breast cancer to determine whether 2 weeks of perioperative aromatase inhibitor before and after surgery improves outcome. Diagnostic core biopsy compared with surgical specimen particularly for Ki67

POETIC Trial Primary outcome – time to recurrence Slight numerical advantage, but not statistically significant Prognostic information on change in Ki67

POETIC Trial Ki67 High Low 19% 9% 4% Diagnostic Core Operative Core Recurrence Rate High 19% Low 9% 4%

POSH Study Over 3000 women recruited between 2000 and 2008 who were 40 or younger at diagnosis of breast cancer. Prospective cohort study – no interventions

POSH Study Weight -54% healthy, 27% overweight, 19% obese Obese more likely to have a larger cancer, a grade 3 cancer and nodal spread. 66% had no family history of breast cancer

POSH Study Most Gene tested. 201 (8%) BRCA1 mutation 2,396 (88%) No mutation

POSH Study Median 8.2 year follow-up No difference in survival between gene carriers and non gene carriers at any time point Irrespective of whether had bilateral mastectomy (21 gene carriers and 10 non gene carriers) Slight benefit in survival for gene carriers who are triple negative

OlympiAD Trial PARP inhibitor - olaparib 300 women with advanced breast cancer and BRCA mutations, HER2 negative Either olaparib orally or standard chemotherapy Olaparib reduced the risk of progression by 42%, delaying progression by 3 months

Miscellaneous FACE trial – Letrozole no better than Anastrozole 22% of non gene carriers have a deficiency in BRCA (somatic not germline) Have BRCA like phenotype behaviour 40% of breast cancers are obesity related Gut microbiome is important for response to immunotherapy

REACT Trial Randomised to have COX 2 inhibitor –Celocoxib or placebo 2500 patients, 450 events No difference between two groups

Risk reduction- Jack Cuzick Half risk of cancer by losing 10kg if obese 19% of cancers caused by smoking Relative risk reduction for low dose aspirin: 0.6 colorectal cancer 0.9 breast cancer 0.5 oesophageal cancer 0.85 prostate cancer IBIS I tamoxifen treat 59 women to prevent one breast cancer at 10 years. SNPs becoming more important Tyrer-Cuzick version 8 – free download

Generations Study - Swerdlow 100,000 women, 40 year follow-up Lots of blood samples and questionnaires 6000 had breast cancer before they started 2500 have developed it after joining Age at thelarche more important tham menarche Risk of DXT (Hodgkins) 5x higher risk if given within 6 months of menarche rather than within 10 years HRT (uses actual usage rather than current like other studies) No risk for oestrogen only. 2.7x for 10 years of combined HRT.

Gene testing Royal Marsden in new breast cancers Criteria: <=40 <= 45 with first degree relative Bilateral, both < 60 Triple negative any age Breast cancer and ovarian Male Gives 10.8 % BRCA positive rate Clinicians order the gene testing after some training

Lobular Cancer Invasive lobular cancer is the 6th most common cancer in women similar rate as Myeloma or Hodgkins 94% ER positive, associated with HRT usage 14% PTEN mutation (3% for IDC) FGFR4 looking to be a promising target Long term prognosis worse, but only after 5 years

Pre-op MRI Prof Ulrich Bick Radiologist Berlin Breast Cancer Res Treat. 2017 Sep;165(2):273-283. doi: 10.1007/s10549-017-4324-3. Epub 2017 Jun 6. Meta-analysis of pre-operative magnetic resonance imaging (MRI) and surgical treatment for breast cancer. Houssami N1, Turner RM2, Morrow M3. Pre-op MRI Prof Ulrich Bick Radiologist Berlin CONCLUSIONS: Pre-operative MRI is associated with increased odds of receiving ipsilateral mastectomy OR 1.39 and contralateral prophylactic mastectomy OR 1.91 as surgical treatment in newly diagnosed BC patients. No effect on rates of re-excision, re-operation or positive margins. _______________________________________________________________________ Br J Surg. 2015 Jul;102(8):883-93. doi: 10.1002/bjs.9797. Epub 2015 Apr 28. Meta-analysis of the effect of preoperative breast MRI on the surgical management of ductal carcinoma in situ. Fancellu A1, Turner RM2, Dixon JM3, Pinna A1, Cottu P1, Houssami N4. CONCLUSION: Preoperative MRI in women with DCIS is not associated with improvement in surgical outcomes. Mastectomy rates not changed by MR.

Pre-op MRI Prognosis is based on Metastases not local disease Very low local recurrence rates anyway Specificity for MRI is very low for <5mm lesions MRI can’t reliably differentiate between relevant and non-relevant disease – picks up a higher % of low grade cancers

Pre-op MRI Canadian study 2015 JAMA Arnaout et al MR increases risk of: Post diagnostic imaging OR 2.09 Post diagnostic biopsies OR 1.74 Post diagnostic staging OR 1.51 Mastectomy OR 1.73 Contralateral mastectomy OR 1.48 Greater than 30 day wait for surgery OR 2.52